Jonathan joined Polaris Partners in 2023 and serves as an entrepreneur partner in the firm’s Singapore research office. In this role, he focuses on building and supporting healthcare companies. He currently works with Polaris portfolio companies including Sunbird Bio and Maxcess Health.
Prior to Polaris, Jonathan was Director in the Life Sciences Team at Temasek International in Singapore, where he managed the firm’s global health care services investment strategy. He co-led investments in the U.S., India, China, Southeast Asia and Latin America. Jonathan was a board observer on several portfolio companies including Columbia Asia Hospitals, Halodoc, Iora Health, Quintiles Transnational Corp., and Zuellig Pharma Holdings Pte Ltd.
Earlier, Jonathan worked at Cowen’s Health Care Banking Team in New York and London, executing mergers and acquisitions, IPOs and private placements.
Jonathan graduated with honors in Economics, majoring in Finance and Accounting, from The Wharton School of the University of Pennsylvania.
The endorsements of current or past portfolio company executives are provided as illustrative examples and designed to demonstrate the benefits to portfolio companies of partnering with us. These statements are primarily aimed at prospective portfolio companies and not intended to solicit investors. The portfolio companies covered in these endorsements do not represent all portfolio company investments we have made. The experiences highlighted in these testimonials are solely those of the executives profiled and may not necessarily represent or be indicative of the current, past, or future experiences of other portfolio companies. Past results and experiences discussed are not indicative, or a guarantee of future results and experiences. We have not provided cash or other type of compensation in exchange for receiving these endorsements. We do not believe there are typically any material conflicts associated with providing these endorsements. The compensation of our portfolio company executives is primarily driven by the performance of their respective portfolio companies and any discretion we exercise in such compensation determinations is not influenced by whether an executive has provided a favorable statement. Additionally, the economic interests of our portfolio companies’ executives are generally well-aligned with ours and those of our investors. Nevertheless, the fact that these endorsements have been provided by individuals whose compensation we exercise a certain level of control over may incentivize them to provide favorable evaluations of their experiences working with us.